HCPCS Level IIdrugActive
J0688
Inj cefazolin sodium, hikma
BETOS: O1E
Effective: 2025-01-01
Referenced in 1 policies
Description
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Cefazolin Sodium
Manufacturer
Hikma Pharmaceuticals USA Inc.
HCPCS Dosage
500 MG
Billing Units
4.0000
2
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.